Navigation Links
Metabolic molecule drives growth of aggressive brain cancer
Date:6/13/2013

COLUMBUS, Ohio A study led by researchers at The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James) has identified an abnormal metabolic pathway that drives cancer-cell growth in a particular glioblastoma subtype. The finding might lead to new therapies for a subset of patients with glioblastoma, the most common and lethal form of brain cancer.

The physician scientists sought to identify glioblastoma subtype-specific cancer stem cells. Genetic analyses have shown that high-grade gliomas can be divided into four subtypes: proneural, neural, classic and mesenchymal.

This study shows that the mesenchymal subtype is the most aggressive subtype, that it has the poorest prognosis among affected patients, and that cancer stem cells isolated from the mesenchymal subtype have significantly higher levels of the enzyme ALDH1A3 compared with the proneural subtype.

The findings, published recently in the Proceedings of the National Academy of Sciences, show that high levels of the enzyme drive tumor growth.

"Our study suggests that ALDH1A3 is a potentially functional biomarker for mesenchymal glioma stem cells, and that inhibiting that enzyme might offer a promising therapeutic approach for high-grade gliomas that have a mesenchymal signature," says principal investigator Ichiro Nakano, MD, PhD, associate professor of neurosurgery at the OSUCCC James. "This indicates that therapies for high-grade gliomas should be personalized, that is, based on the tumor subtype instead of applying one treatment to all patients," he says.

The National Cancer Institute estimates that 23,130 Americans will be diagnosed with brain and other nervous system tumors in 2013, and that 14,000 people will die of these malignancies. Glioblastoma accounts for about 15 percent of all brain tumors, is resistant to current therapies and has a survival as short as 15 months after diagnosis.

Little is known, however, about the metabolic pathways that drive the growth of individual glioblastoma subtypes knowledge that is crucial for developing novel and effective targeted therapies that might improve treatment for these lethal tumors.

For this study, Nakano and his collaborators used cancer cells from 40 patients with high-grade gliomas, focusing on tumor cells with a stem-cell signature. The researchers then used microarray analysis and pre-clinical animal assays to identify two predominant glioblastoma subtypes, proneural and mesenchymal.

Key technical findings include:

  • Genes involved in glycolysis and gluconeogenesis, particularly ALDH1A3, were significantly up-regulated in mesenchymal glioma stem cells compared to proneural stem cells;
  • Mesenchymal glioma stem cells show significantly higher radiation resistance and high expression of DNA-repair genes;
  • Radiation induces transformation of proneural glioma stem cells into mesenchymal-like glioma stem cells that are highly resistant to radiation treatment; inhibiting the ALDH1 pathway reverses this resistance.
  • Inhibiting ALDH1A3-mediated pathways slows the growth of mesenchymal glioma stem cells and might provide a promising therapeutic approach for glioblastomas with a mesenchymal signature.

"Overall, our data suggest that a novel signaling mechanism underlies the transformation of proneural glioma stem cells to mesenchymal-like cells and their maintenance as stem-like cells," Nakano says. Currently, their discoveries are in provision patent application, led by the Technology Licensing Office at University of Pittsburgh.


'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. Metabolic PET imaging provides earlier warning of coronary disease
2. hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offer Improved hCG Diets to Counteract Metabolic Slowdown
3. Roundworm quells obesity and related metabolic disorders
4. Metabolic disorders predict the hardening of the arterial walls already in childhood
5. Epoxide hydrolase inhibition and Thiazolidinediones: A therapy for cardiometabolic syndrome
6. Monounsaturated fats reduce metabolic syndrome risk
7. Monosaturated fats reduce metabolic syndrome risk
8. Altman Fitness Launches the Metabolic Typing - Customized Nutrition Plan
9. EU funds research project on obesity and metabolic complications
10. Selexis SA Announces Publication in Metabolic Engineering of Data Demonstrating Improvement of Therapeutic Protein Secretion with Engineered CHO Cells
11. Recon 2 modeling may help tailor treatments for patients with metabolic diseases, cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... CDRH Enforcement Trends: , Back to the Future , Feb. ... , As Winston Churchill said, “Those who don’t learn from history are doomed to repeat ... when they come knocking this year. But that takes time. , Take a close ...
(Date:2/12/2016)... ... ... Each year, the American Physical Therapy Association (APTA) offers a Combined Sections ... Center. Almost 10,000 physical therapists across the country are expected to attend this annual ... chosen field and network with their colleagues. As in years past, HydroWorx is ...
(Date:2/12/2016)... ... , ... Coco Libre, the maker of coconut water beverages with a purpose, ... Event. Coco Libre will offer musicians and celebrities the company’s signature Organic Coconut Water, ... gifting suite, held this year at the W Hollywood Hotel, has become a pre-show ...
(Date:2/12/2016)... ... February 12, 2016 , ... The ThedaCare Center for Healthcare ... Hospital on April 5-7. The series is a multi-day, multi-workshop event designed to ... cover a broad range of topics, including coaching skills, the scientific method of ...
(Date:2/12/2016)... PITTSBURGH, Pa. (PRWEB) , ... February 12, 2016 , ... ... space heaters. , This winter the West Penn Burn Center, part of ... Fire Company #1, to bring you the “Space Heaters Need Space” campaign. ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)...  Kindred Biosciences, Inc. (NASDAQ: KIN ), a ... of pets, today announced the submission to FDA of ... Application (NADA) for Zimeta™ (dipyrone injection, KIND-012).  Positive topline ... for the control of pyrexia (fever) in horses were ... --> The Chemistry, Manufacturing, and Controls ...
(Date:2/11/2016)...   Health 2.0 , the premiere showcase and ... today " 10 Year Global Retrospective ", a platform ... past ten years.   --> ... has served as the preeminent thought-leader in the health ... technologies, companies, innovators, and patient-activists through an array of ...
(Date:2/11/2016)... , Feb. 11, 2016  MiMedx Group, Inc. (NASDAQ: ... human amniotic membrane and other birth tissues, human skin ... develop and market advanced products and therapies, announced today ... 2016 Global Healthcare Conference in New York ... CEO, Michael J. Senken , Chief Financial Officer ...
Breaking Medicine Technology: